No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis.

Tissue inhibitor of metalloproteinase (TIMP2) is involved in the regulation of matrix metalloproteinase 2 (MMP2) and shown to implicate in cancer development and progression. The results from the published studies based on the association between TIMP2 -418 G>C polymorphism and cancer risk are in...

Full description

Bibliographic Details
Main Authors: Raju K Mandal, Naseem Akhter, Shafiul Haque, Aditya K Panda, Rama D Mittal, Mohammed A A Alqumber
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4138026?pdf=render
id doaj-d9921c70d88146459881dbe72b6549c5
record_format Article
spelling doaj-d9921c70d88146459881dbe72b6549c52020-11-24T21:26:33ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0198e8818410.1371/journal.pone.0088184No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis.Raju K MandalNaseem AkhterShafiul HaqueAditya K PandaRama D MittalMohammed A A AlqumberTissue inhibitor of metalloproteinase (TIMP2) is involved in the regulation of matrix metalloproteinase 2 (MMP2) and shown to implicate in cancer development and progression. The results from the published studies based on the association between TIMP2 -418 G>C polymorphism and cancer risk are inconsistent. In this meta-analysis, we aimed to evaluate the potential association between TIMP2 -418 G>C polymorphism and cancer risk.We searched PubMed (Medline) and EMBASE web databases to cover all studies based on relationship of TIMP2 -418 G>C polymorphism and risk of cancer until October 2013. The meta-analysis was performed for selected case-control studies and pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for all genetic models.A total of 2225 cancer cases and 2532 controls were included from ten eligible case-control studies. Results from overall pooled analysis suggested no evidence of significant risk between TIMP2 -418 G>C polymorphism and cancer risk in any of the genetic models, such as, allele (C vs. G: OR = 1.293, 95% CI = 0.882 to 1.894, p = 0.188), homozygous (CC vs. GG: OR = 0.940, 95% CI = 0.434 to 2.039, p = 0.876), heterozygous (GC vs. GG: OR = 1.397, 95% CI = 0.888 to 2.198, p = 0.148), dominant (CC+GC vs. GG: OR = 1.387, 95% CI = 0.880 to 2.187, p = 0.159) and recessive (CC vs. GG+GC: OR = 0.901, 95% CI = 0.442 to 1.838, p = 0.774) models. No evidence of publication bias was detected during the analysis.The present meta-analysis suggests that the TIMP2 -418 G>C polymorphism may not be involved in predisposing risk factor for cancer in overall population. However, future larger studies with group of populations are needed to analyze the possible correlation.http://europepmc.org/articles/PMC4138026?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Raju K Mandal
Naseem Akhter
Shafiul Haque
Aditya K Panda
Rama D Mittal
Mohammed A A Alqumber
spellingShingle Raju K Mandal
Naseem Akhter
Shafiul Haque
Aditya K Panda
Rama D Mittal
Mohammed A A Alqumber
No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis.
PLoS ONE
author_facet Raju K Mandal
Naseem Akhter
Shafiul Haque
Aditya K Panda
Rama D Mittal
Mohammed A A Alqumber
author_sort Raju K Mandal
title No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis.
title_short No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis.
title_full No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis.
title_fullStr No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis.
title_full_unstemmed No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis.
title_sort no correlation between timp2 -418 g>c polymorphism and increased risk of cancer: evidence from a meta-analysis.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description Tissue inhibitor of metalloproteinase (TIMP2) is involved in the regulation of matrix metalloproteinase 2 (MMP2) and shown to implicate in cancer development and progression. The results from the published studies based on the association between TIMP2 -418 G>C polymorphism and cancer risk are inconsistent. In this meta-analysis, we aimed to evaluate the potential association between TIMP2 -418 G>C polymorphism and cancer risk.We searched PubMed (Medline) and EMBASE web databases to cover all studies based on relationship of TIMP2 -418 G>C polymorphism and risk of cancer until October 2013. The meta-analysis was performed for selected case-control studies and pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for all genetic models.A total of 2225 cancer cases and 2532 controls were included from ten eligible case-control studies. Results from overall pooled analysis suggested no evidence of significant risk between TIMP2 -418 G>C polymorphism and cancer risk in any of the genetic models, such as, allele (C vs. G: OR = 1.293, 95% CI = 0.882 to 1.894, p = 0.188), homozygous (CC vs. GG: OR = 0.940, 95% CI = 0.434 to 2.039, p = 0.876), heterozygous (GC vs. GG: OR = 1.397, 95% CI = 0.888 to 2.198, p = 0.148), dominant (CC+GC vs. GG: OR = 1.387, 95% CI = 0.880 to 2.187, p = 0.159) and recessive (CC vs. GG+GC: OR = 0.901, 95% CI = 0.442 to 1.838, p = 0.774) models. No evidence of publication bias was detected during the analysis.The present meta-analysis suggests that the TIMP2 -418 G>C polymorphism may not be involved in predisposing risk factor for cancer in overall population. However, future larger studies with group of populations are needed to analyze the possible correlation.
url http://europepmc.org/articles/PMC4138026?pdf=render
work_keys_str_mv AT rajukmandal nocorrelationbetweentimp2418gcpolymorphismandincreasedriskofcancerevidencefromametaanalysis
AT naseemakhter nocorrelationbetweentimp2418gcpolymorphismandincreasedriskofcancerevidencefromametaanalysis
AT shafiulhaque nocorrelationbetweentimp2418gcpolymorphismandincreasedriskofcancerevidencefromametaanalysis
AT adityakpanda nocorrelationbetweentimp2418gcpolymorphismandincreasedriskofcancerevidencefromametaanalysis
AT ramadmittal nocorrelationbetweentimp2418gcpolymorphismandincreasedriskofcancerevidencefromametaanalysis
AT mohammedaaalqumber nocorrelationbetweentimp2418gcpolymorphismandincreasedriskofcancerevidencefromametaanalysis
_version_ 1725978990263402496